The rationale of the investigators testing these drugs as possible treatments for COVID-19 is based on the possible prevention of cytokine storm through the influence of the S1R–IRE1 pathway in the case of fluvoxamine [89], the inhibition of IL-6 for fluoxetine [92], and the anti-inflammatory effect decreasing the plasma level of TNF-α in the case of tramadol [91]. The gene discussed is TNF; the disease is COVID-19.